JP2012512873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512873A5 JP2012512873A5 JP2011542246A JP2011542246A JP2012512873A5 JP 2012512873 A5 JP2012512873 A5 JP 2012512873A5 JP 2011542246 A JP2011542246 A JP 2011542246A JP 2011542246 A JP2011542246 A JP 2011542246A JP 2012512873 A5 JP2012512873 A5 JP 2012512873A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- acceptable salt
- pharmaceutically acceptable
- compound according
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 6
- -1 CF 3 Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- WGBFSSQNXAZCGW-UHFFFAOYSA-N 2-methyl-6-(4-methylpiperazin-1-yl)-9-(oxan-4-yl)-8-[2-(trifluoromethyl)phenyl]purine Chemical compound C1CN(C)CCN1C1=NC(C)=NC2=C1N=C(C=1C(=CC=CC=1)C(F)(F)F)N2C1CCOCC1 WGBFSSQNXAZCGW-UHFFFAOYSA-N 0.000 claims 1
- UCMNDPDJRSEZPL-UHFFFAOYSA-N 8-(2-chlorophenyl)-2-methyl-6-(4-methylpiperazin-1-yl)-9-(oxan-4-yl)purine Chemical group C1CN(C)CCN1C1=NC(C)=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1CCOCC1 UCMNDPDJRSEZPL-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- PCLIUMMFWRGXRK-UHFFFAOYSA-N methyl azetidine-1-carboxylate Chemical compound COC(=O)N1CCC1 PCLIUMMFWRGXRK-UHFFFAOYSA-N 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 150000003212 purines Chemical class 0.000 claims 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13858908P | 2008-12-18 | 2008-12-18 | |
| US61/138,589 | 2008-12-18 | ||
| PCT/US2009/067249 WO2010080306A1 (en) | 2008-12-18 | 2009-12-09 | Purine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012512873A JP2012512873A (ja) | 2012-06-07 |
| JP2012512873A5 true JP2012512873A5 (enExample) | 2013-01-24 |
| JP5559812B2 JP5559812B2 (ja) | 2014-07-23 |
Family
ID=41719189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542246A Expired - Fee Related JP5559812B2 (ja) | 2008-12-18 | 2009-12-09 | プリン化合物 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8252798B2 (enExample) |
| EP (1) | EP2379555B1 (enExample) |
| JP (1) | JP5559812B2 (enExample) |
| KR (1) | KR101319630B1 (enExample) |
| CN (1) | CN102256977B (enExample) |
| AR (1) | AR075104A1 (enExample) |
| AU (1) | AU2009335997B2 (enExample) |
| BR (1) | BRPI0923195A2 (enExample) |
| CA (1) | CA2746740C (enExample) |
| CL (1) | CL2011001464A1 (enExample) |
| CO (1) | CO6390101A2 (enExample) |
| CR (1) | CR20110340A (enExample) |
| DO (1) | DOP2011000196A (enExample) |
| EA (1) | EA018386B1 (enExample) |
| EC (1) | ECSP11011151A (enExample) |
| ES (1) | ES2536880T3 (enExample) |
| HN (1) | HN2011001700A (enExample) |
| IL (1) | IL213167A (enExample) |
| MA (1) | MA32904B1 (enExample) |
| MX (1) | MX2011006442A (enExample) |
| NZ (1) | NZ593088A (enExample) |
| PA (1) | PA8851501A1 (enExample) |
| PE (1) | PE20110999A1 (enExample) |
| SG (1) | SG172253A1 (enExample) |
| TN (1) | TN2011000291A1 (enExample) |
| TW (1) | TWI376378B (enExample) |
| UA (1) | UA104010C2 (enExample) |
| WO (1) | WO2010080306A1 (enExample) |
| ZA (1) | ZA201103943B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2923734B1 (en) * | 2009-03-13 | 2018-01-10 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Purine analogues and their use as immunosuppressive agents |
| EP2470508A1 (en) | 2009-08-28 | 2012-07-04 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| US20130096104A1 (en) * | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| AR080711A1 (es) | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
| CN102803263B (zh) * | 2010-03-31 | 2014-12-17 | 伊莱利利公司 | 用作cb2激动剂的嘌呤化合物 |
| RU2013114352A (ru) | 2010-09-15 | 2014-10-20 | Ф. Хоффманн-Ля Рош Аг | Азабензотиазолы, композиции и способы применения |
| KR20140009259A (ko) | 2010-11-19 | 2014-01-22 | 에프. 호프만-라 로슈 아게 | 피라졸로피리딘 및 tyk2 억제제로서 이의 용도 |
| JP5945554B2 (ja) | 2011-02-25 | 2016-07-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター） |
| MX392150B (es) | 2011-02-25 | 2025-03-21 | Arena Pharm Inc | Moduladores de receptores canabinoides. |
| US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| BR112014006643A2 (pt) * | 2011-09-20 | 2017-04-04 | Hoffmann La Roche | compostos de imidazopiridina, composições e métodos de uso dos mesmos |
| US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
| PE20151140A1 (es) * | 2012-08-16 | 2015-08-07 | Janssen Pharmaceutica Nv | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| BR112015027394A8 (pt) * | 2013-05-02 | 2018-01-30 | Hoffmann La Roche | derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| WO2017052394A1 (en) * | 2015-09-23 | 2017-03-30 | Uniwersytet Jagielloński | Imidazopyridine compounds and their use as 5-ht6 receptor ligands |
| WO2018137176A1 (en) * | 2017-01-25 | 2018-08-02 | Eli Lilly And Company | Treatment for nonalcoholic steatohepatitis and fibrosis |
| WO2017181317A1 (en) * | 2016-04-18 | 2017-10-26 | Eli Lilly And Company | Treatment for nonalcoholic steatohepatitis and fibrosis |
| WO2017184412A1 (en) | 2016-04-18 | 2017-10-26 | Eli Lilly And Company | Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis |
| EP3558996A4 (en) * | 2016-12-21 | 2020-08-05 | Research Triangle Institute, International | DIARYLPURINE DERIVATIVES WITH ENHANCED BIOAVAILABILITY |
| US20200078358A1 (en) | 2017-05-08 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds and Methods for Treatment of Visceral Pain |
| WO2024017227A1 (zh) * | 2022-07-21 | 2024-01-25 | 长春金赛药业有限责任公司 | 取代的稠环大麻素受体化合物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60260579A (ja) * | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| NZ225447A (en) | 1987-07-20 | 1991-12-23 | Merck & Co Inc | Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions |
| US5057517A (en) * | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
| GB0003960D0 (en) * | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US20050043327A1 (en) * | 2003-08-21 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050153989A1 (en) | 2004-01-13 | 2005-07-14 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| CN101044143A (zh) * | 2004-10-22 | 2007-09-26 | 辉瑞产品公司 | 制备嘌呤化合物的方法 |
| WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
| HRP20120786T1 (hr) * | 2006-02-02 | 2012-11-30 | Millennium Pharmaceuticals, Inc. | Inhibitori aktivirajuä†eg enzima e1 |
| JP2013512245A (ja) * | 2009-11-24 | 2013-04-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 脂肪酸合成酵素阻害剤としてのアザベンズイミダゾール |
| AR080711A1 (es) * | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
-
2009
- 2009-09-12 UA UAA201107563A patent/UA104010C2/ru unknown
- 2009-12-01 AR ARP090104628A patent/AR075104A1/es not_active Application Discontinuation
- 2009-12-01 PA PA20098851501A patent/PA8851501A1/es unknown
- 2009-12-04 TW TW098141555A patent/TWI376378B/zh not_active IP Right Cessation
- 2009-12-09 JP JP2011542246A patent/JP5559812B2/ja not_active Expired - Fee Related
- 2009-12-09 MX MX2011006442A patent/MX2011006442A/es active IP Right Grant
- 2009-12-09 CN CN200980150689.3A patent/CN102256977B/zh not_active Expired - Fee Related
- 2009-12-09 EP EP09768474.0A patent/EP2379555B1/en not_active Not-in-force
- 2009-12-09 CA CA2746740A patent/CA2746740C/en not_active Expired - Fee Related
- 2009-12-09 SG SG2011044773A patent/SG172253A1/en unknown
- 2009-12-09 US US12/633,812 patent/US8252798B2/en not_active Expired - Fee Related
- 2009-12-09 AU AU2009335997A patent/AU2009335997B2/en not_active Ceased
- 2009-12-09 ES ES09768474.0T patent/ES2536880T3/es active Active
- 2009-12-09 KR KR1020117014000A patent/KR101319630B1/ko not_active Expired - Fee Related
- 2009-12-09 NZ NZ593088A patent/NZ593088A/xx not_active IP Right Cessation
- 2009-12-09 PE PE2011001219A patent/PE20110999A1/es not_active Application Discontinuation
- 2009-12-09 WO PCT/US2009/067249 patent/WO2010080306A1/en not_active Ceased
- 2009-12-09 EA EA201170832A patent/EA018386B1/ru not_active IP Right Cessation
- 2009-12-09 BR BRPI0923195A patent/BRPI0923195A2/pt not_active Application Discontinuation
-
2011
- 2011-05-26 IL IL213167A patent/IL213167A/en not_active IP Right Cessation
- 2011-05-27 ZA ZA2011/03943A patent/ZA201103943B/en unknown
- 2011-06-09 TN TN2011000291A patent/TN2011000291A1/fr unknown
- 2011-06-14 MA MA33947A patent/MA32904B1/fr unknown
- 2011-06-16 CL CL2011001464A patent/CL2011001464A1/es unknown
- 2011-06-17 HN HN2011001700A patent/HN2011001700A/es unknown
- 2011-06-17 EC EC2011011151A patent/ECSP11011151A/es unknown
- 2011-06-17 CR CR20110340A patent/CR20110340A/es unknown
- 2011-06-17 DO DO2011000196A patent/DOP2011000196A/es unknown
- 2011-06-23 CO CO11079298A patent/CO6390101A2/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11065236B2 (en) | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | |
| HRP20150938T1 (hr) | Derivati purina namijenjeni upotrebi u lijeäśenju alergijskih, upalnih i zaraznih bolesti | |
| JP2013519645A5 (enExample) | ||
| Gudmundsson et al. | Imidazo [1, 2-a] pyridines with potent activity against herpesviruses | |
| JP2016505010A5 (enExample) | ||
| WO2019212991A1 (en) | C26-linked rapamycin analogs as mtor inhibitors | |
| JP2016523908A5 (enExample) | ||
| JP2016523907A5 (enExample) | ||
| AU2010319999A1 (en) | 2'-Fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections | |
| JP2018500372A5 (enExample) | ||
| JP2013049719A (ja) | Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 | |
| NZ593088A (en) | 8-([Hetero]aryl)-6-(4-alkyl-piperazin-1-yl)-9H-purine derivatives and uses thereof in the treatment of pain | |
| JP2016530283A5 (enExample) | ||
| JP2012532131A5 (enExample) | ||
| NZ627826A (en) | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide | |
| CR10419A (es) | Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios | |
| JP2014505735A5 (enExample) | ||
| CA2663401A1 (en) | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors | |
| Manna et al. | Anticancer potential and structure activity studies of purine and pyrimidine derivatives: an updated review | |
| JP2013528640A5 (enExample) | ||
| HRP20141258T1 (hr) | 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat | |
| NZ610012A (en) | Compositions and methods of treating pulmonary hypertension | |
| ECSP13012654A (es) | Composiciones farmacéuticas | |
| PE20060833A1 (es) | Derivados de purina como agonistas del receptor a2a de adenosina | |
| JP2013523740A5 (enExample) |